Zibotentan better renal scleroderma outcome study (ZEBRA)

• Research type

  Research Study

• Full title

  A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma

• IRAS ID

  136274

• Contact name

  Christopher Denton

• Contact email

  c.denton@ucl.ac.uk

• Eudract number

  2013-003200-39

• ISRCTN Number

  n/a

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  14/LO/0120

• Date of REC Opinion

  28 Jan 2014

• REC opinion

  Further Information Favourable Opinion